New study related to glutathione and cancer

Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A
Promising Intervention Study
Immunotec Inc. announced today the successful completion of a multi-center
randomized, double-blind clinical trial on cancer-related weight loss
(cachexia) in lung cancer patients which was performed in collaboration with
various Canadian clinical centers. The research concluded that patients
treated with IMN 1207 showed significant increases in body weight (Tozer et
al. Antioxidants & Redox Signaling (2008) 10:395-402). Immunotec also
announced the initiation of a follow-up study to confirm the positive
results.

Immunotec's new study included 66 patients with advanced lung cancer
receiving state of the art chemotherapy or radiotherapy. The patients had
already suffered significant involuntary weight-loss prior to treatment.
During a six month treatment period the patients were given either casein, a
protein supplement low in cysteine which is widely used in clinical
nutrition ("placebo") or IMN 1207, a the research formulation of the
undenatured whey protein Immunocal®. The results showed that patients in the
placebo group continued to lose weight whereas patients treated with IMN
1207 showed a significant increase in body weight. Incidentally, these
patients also showed an increase in strength and quality of life parameters.
This study showed for the first time that cancer-related weight loss
(cachexia) can be prevented by a single source of protein.

Research wrote:

> Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A
> Promising Intervention Study
> Immunotec Inc. announced today the successful completion of a multi-center
> randomized, double-blind clinical trial on cancer-related weight loss
> (cachexia) in lung cancer patients which was performed in collaboration with
> various Canadian clinical centers. The research concluded that patients
> treated with IMN 1207 showed significant increases in body weight (Tozer et
> al. Antioxidants & Redox Signaling (2008) 10:395-402). Immunotec also
> announced the initiation of a follow-up study to confirm the positive
> results.

Could not find it; here's the locations of the afore-mentioned one.
*) Montreal General Hospital (McGill University teaching hospital)
Montreal, Quebec, Canada
- (*) Cross Cancer Institute, Alberta Cancer Board (University of Alberta
affiliate) Edmonton, Alberta, Canada
- (*) Jewish General Hospital (McGill University teaching hospital)
Montreal, Quebec, Canada
- (*) Juravinski Cancer Centre (McMaster University and Hamilton Health
Sciences affiliate) Hamilton, Ontario,Canada.
- (*) Allan Blair Cancer Centre (a division of Saskatchewan Cancer
Foundation) Regina, Saskatchewan, Canada.
Several people involved with the compary work at McGill University.
Small cohort. We'll watch for a multi-centre, multi-country clinical trial.
J

> Immunotec's new study included 66 patients with advanced lung cancer
> receiving state of the art chemotherapy or radiotherapy. The patients had
> already suffered significant involuntary weight-loss prior to treatment.
> During a six month treatment period the patients were given either casein, a
> protein supplement low in cysteine which is widely used in clinical
> nutrition ("placebo") or IMN 1207, a the research formulation of the
> undenatured whey protein Immunocal®. The results showed that patients in the
> placebo group continued to lose weight whereas patients treated with IMN
> 1207 showed a significant increase in body weight. Incidentally, these
> patients also showed an increase in strength and quality of life parameters.
> This study showed for the first time that cancer-related weight loss
> (cachexia) can be prevented by a single source of protein.

See the study here:
http://www.liebertonline.com/doi/pdf...19?cookieSet=1

The rold of glutathione and cancer treatment and prevention is ignored in
this newsgroup for some odd reason.

PubMed has over 7000 publications about them.
http://www.ncbi.nlm.nih.gov/sites/en...hione%20cancer

and over 5000 re chemotherapy and glutathione
http://www.ncbi.nlm.nih.gov/sites/en...20chemotherapy

over 12,000 re glutathione and tumors
http://www.ncbi.nlm.nih.gov/sites/en...thione%20tumor



"J" <nswex@nalid;non> wrote in message
news:47912558.CCD38DE9@execulink.com...
> Research wrote:
>
>> Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A
>> Promising Intervention Study
>> Immunotec Inc. announced today the successful completion of a
>> multi-center
>> randomized, double-blind clinical trial on cancer-related weight loss
>> (cachexia) in lung cancer patients which was performed in collaboration
>> with
>> various Canadian clinical centers. The research concluded that patients
>> treated with IMN 1207 showed significant increases in body weight (Tozer
>> et
>> al. Antioxidants & Redox Signaling (2008) 10:395-402). Immunotec also
>> announced the initiation of a follow-up study to confirm the positive
>> results.
>
> Could not find it; here's the locations of the afore-mentioned one.
> *) Montreal General Hospital (McGill University teaching hospital)
> Montreal, Quebec, Canada
> - (*) Cross Cancer Institute, Alberta Cancer Board (University of
> Alberta
> affiliate) Edmonton, Alberta, Canada
> - (*) Jewish General Hospital (McGill University teaching hospital)
> Montreal, Quebec, Canada
> - (*) Juravinski Cancer Centre (McMaster University and Hamilton Health
> Sciences affiliate) Hamilton, Ontario,Canada.
> - (*) Allan Blair Cancer Centre (a division of Saskatchewan Cancer
> Foundation) Regina, Saskatchewan, Canada.
> Several people involved with the compary work at McGill University.
> Small cohort. We'll watch for a multi-centre, multi-country clinical
> trial.
> J

They have medical patents for the treatment and prevention of cancer.

http://patents.ic.gc.ca/cipo/cpd/en/...7/summary.html

http://patft.uspto.gov/netacgi/nph-P...l&RS=immunocal

F.D.A. site slide show about glutathione:
http://www.fda.gov/ohrms/dockets/ac/..._05/sld001.htm




>
>> Immunotec's new study included 66 patients with advanced lung cancer
>> receiving state of the art chemotherapy or radiotherapy. The patients had
>> already suffered significant involuntary weight-loss prior to treatment.
>> During a six month treatment period the patients were given either
>> casein, a
>> protein supplement low in cysteine which is widely used in clinical
>> nutrition ("placebo") or IMN 1207, a the research formulation of the
>> undenatured whey protein Immunocal®. The results showed that patients in
>> the
>> placebo group continued to lose weight whereas patients treated with IMN
>> 1207 showed a significant increase in body weight. Incidentally, these
>> patients also showed an increase in strength and quality of life
>> parameters.
>> This study showed for the first time that cancer-related weight loss
>> (cachexia) can be prevented by a single source of protein.
>

Research wrote:

> >>Immunotec also
> >> announced the initiation of a follow-up study to confirm the positive
> >> results.
> >
> > Could not find it;
> > We'll watch for a multi-centre, multi-country clinical trial.
> > J
>